A concentrated opioid is being sold as “just kratom”
The DEA moved to ban it. The threshold that decides which products are actually banned is open for public comment until July 31st.
A legal, plant-branded product that acts like an opioid.
How 7-OH differs from the kratom leaf.
The threshold that decides what gets banned.
Who benefits from where the line lands.
Who decides the 7-OH threshold and how? The public has a say.
A legal, plant-branded product that acts like an opioid.
There’s a product sold near the phone chargers and the energy shots at a lot of gas stations. It comes in a bright pouch. It’s cheap, it’s legal in most states, and it’s marketed as a plant. The pouch might say “kratom,” or “natural,” or “wellness.” What’s often inside is a concentrated dose of 7-hydroxymitragynine, or 7-OH, which acts on the same brain receptors as morphine.
On July 1st, the Drug Enforcement Administration moved to place 7-OH and three related substances in Schedule I, the category reserved for drugs with no accepted medical use. The FDA backed the risk finding. The danger is real, and it’s been widely reported.
Almost none of that coverage went to the fight that’s still open. Concentrated 7-OH fell outside the drug rules as written. The exact threshold that decides which products get banned is open for public comment until the end of the month.
How 7-OH differs from the kratom leaf.
Kratom is a leaf. Its main active ingredient is mitragynine. Mitragynine works on the same brain receptor as morphine, but far more weakly, which is why a cup of kratom tea reads as mild. 7-OH is a second compound, a byproduct your body makes in small amounts as it breaks mitragynine down. In the raw leaf it’s barely present, a trace. But at that same opioid receptor it’s substantially more potent than mitragynine, and it behaves more like a full-strength opioid than a weak one.
Companies concentrate that trace to levels the leaf never reaches. They press it into tablets and shots and sell it as “kratom,” even though what’s inside acts like an opioid.
Vape makers pulled this move by swapping nicotine for a synthetic analog that isn’t technically nicotine, then selling it as “PMTA exempt.” (Premarket Tobacco Product Application is the FDA review process a company must go through to legally sell a new tobacco or nicotine product in the US.)
Supplement companies do it by self-declaring new ingredients safe and skipping the FDA’s clearance process. It’s the same “natural = safe” loophole time and again: something sounds like food or a plant, so the rules go easy on it, even when it acts like a drug.
Drug rules work by naming specific chemicals, which makes them easy to sidestep. Tweak the molecule into a cousin the rule hasn’t caught up to, and you’re back in business, which is exactly what concentrated 7-OH is.
The threshold that decides what gets banned.
Now the Department of Health and Human Services has opened a request for information, a public comment window, asking a narrow, decisive question: is the threshold right?
The DEA drew the line at 0.050% of 7-OH by dry weight in a botanical product, or more than 1.00 mg in a synthetic one. Virtually every concentrated 7-OH product on the shelf sits well above that. The naturally occurring 7-OH in leaf kratom sits below it. So the line, as drawn, bans the concentrate and leaves the leaf alone.
Who benefits from where the line lands.
The established kratom trade groups, including the American Kratom Association and the Global Kratom Coalition, lobbied for scheduling 7-OH. Their argument is that concentrated 7-OH “isn’t kratom.” Allowing gas-station opioid tablets to be labeled kratom, they say, threatens the legitimacy and the legality of the leaf they sell. The kratom trade has a commercial stake in where the line lands.
Who decides the 7-OH threshold and how? The public has a say.
A Notice of Intent and an RFI aren’t the finish line, just steps in a process that’s still open. The comment period runs through July 31st, so the threshold can still move. Until then, the docket (HHS-OASH-2026-0232) stays open. It’s the easiest place for a clinician, a poison-control director, or a parent to put evidence on the record about what counts as a hazard.
HHS is collecting the comments and will hand them to Acting Attorney General Todd Blanche. The DEA sets the schedule while the Blanch makes the final decision. The people most likely to weigh in are those whose product would remain legal if the line holds, and they’ve been watching this docket closely.
Prescription opioids were sold as safe when they weren’t, and by the time the labels caught up, people were already dependent or dead. 7-OH is a potent opioid sold as “just kratom,” and most people buying it don’t know how strong it is.
How this ends depends on where the threshold gets set and who comments before it does.